ArticleFrontiers in nutrition2025
Long-term trends in the burden of cancer attributable to high body mass index in China from 1990 to 2021.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection.Ecancermedicalscience · 2026Review
- Rising burden of pancreatic cancer in China: Trends, drivers, and future projections.PloS one · 2025Article
- Burden of colorectal cancer attributable to dietary risks in China from 1990 to 2021: findings from the Global Burden of Disease Study 2021.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High body mass index (BMI) is a well-established modifiable risk factor for multiple cancer types. However, the long-term trends and demographic patterns of total cancer burden attributable to high BMI in China have not been fully characterized. This study aimed to assess the magnitude, temporal trends, and demographic drivers of BMI-related cancer burden in China from 1990 to 2021. Methods: Data on total cancer burden attributable to high BMI were obtained from the Global Burden of Disease Study 2021. Key indicators included deaths, disability-adjusted life years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs). Age-standardized rates (ASRs) were estimated by sex and age group. Joinpoint regression and age-period-cohort (APC) analyses were performed to assess trends, and decomposition analysis was used to quantify the contributions of population growth, population aging, and epidemiological changes. Results: In 2021, high BMI accounted for 58,745 cancer deaths and 1.66 million DALYs in China. Compared with 1990, age-standardized death and DALY rates increased by approximately 1.7-fold and 1.6-fold, respectively. Males had higher age-standardized rates of deaths, DALYs, and YLLs, while females exhibited higher YLD rates. The burden peaked in the 50-69 age group and varied by sex across age strata. Colorectal, liver, kidney, and breast cancers were the largest contributors to the BMI-related cancer burden. APC analysis revealed growing burden across age and period dimensions, with higher DALY and mortality rates observed in more recent birth cohorts. Decomposition analysis showed that the increase in deaths was mainly driven by epidemiological change and population growth, while DALY increases were influenced by all three components, with a stronger impact in males. Conclusion: The burden of cancer attributable to high BMI in China has risen substantially over the past three decades, with clear sex, age, and cohort-specific differences. Comprehensive public health strategies targeting obesity prevention and cancer control are urgently needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.